Fusion Antibodies News

Fsn1006h Bispecific Antibody awarded European patent

Fusion Antibodies, an antibody humanization and cell line development CRO, have today announced the further preclinical development of Fsn1006h bispecific antibody and the granting of a European patent for the same. Fusion’s Fsn1006h antibody…

Fusion Antibodies featured in EBR magazine

Check out our company’s profile in the summer edition of European Biopharmaceutical Review. You can read a digital copy via http://flk.bz/W38U European Biopharmaceutical Review (EBR) is a quarterly magazine dedicated to the…

Fusion Antibodies nominated for Irish Times Intertradeireland Innovation Award

Leading UK contract research organisation and antibody humanization specialist, Fusion Antibodies, has been shortlisted for a prestigious Irish Times InterTradeIreland Innovation Award. Leading UK contract research organisation and antibody…

Humanized antibody for invasive pulmonary aspergillosis: Fusion Antibodies and ISCA diagnostic collaboration

Fusion Antibodies and ISCA diagnostics are announcing successful development of a humanized version of ISCA Diagnostic’s Aspergillus-specific monoclonal antibody JF5. The project has taken place over the past 10 months and today marks its…

Fusion Antibodies develop high expression level stable cell line for ISCA Diagnostics

FUSION ANTIBODIES DEVELOP HIGH EXPRESSION LEVEL STABLE CELL LINE FOR ISCA DIAGNOSTICS Fusion Antibodies Develop High Expression Level Stable Cell Line for ISCA Diagnostics Fusion Antibodies and ISCA diagnostics are happy to announce…

Antibodies Alma Mater – Queen’s University

In 2001, Fusion Antibodies emerged from Queen’s University in Belfast. We are happy to still be working together in the field of novel medicine. Queen’s University Belfast is a member of the Russell Group of 24 leading UK research-intensive…

Fusion Antibodies Ltd and Chiome Bioscience Inc collaboration in chicken antibody sequences humanization

Fusion Antibodies have entered into collaboration with Japanese Biotechnology company Chiome Bioscience to humanize chicken antibodies. The project will use the capabilities of the Fusion Antibodies next generation Antibody Humanization CDRx…

Fusion Antibodies helps students examine a career in Stratified Medicine

Eighteen students took part in a work experience event sponsored by Fusion Antibodies and hosted by the University of Ulster on 1 and 2 July 2014. Fusion Antibodies understand that the best way to learn is by experience. That is…

Antibodies inhibit cathepsin S to stop metastasis – news from Memorial Sloan Kettering research team

One of the most important goals of modern medical research is to find an effective and non invasive method of a cancer treatment. Immunotherapy and Stratified Medicine have a great potential to become a leading approach to cancer therapy. The…

Fusion Antibodies lead drug targeted at pancreatic cancer

A novel pre-clinical antibody drug being developed by Fusion Antibodies (Belfast, NI) is being targeted at Pancreatic Cancer. Early in-vitro data has shown significant efficacy in Pancreatic Cancer cell lines and the Company is now seeking…

Fusion Antibodies to humanize Avipero’s Integrin antibody platform

Fusion Antibodies Ltd has today announced a collaboration with the regenerative medicine company Avipero Ltd for humanization of their integrin antibody platform. The antibody engineering and humanization program partnered with Fusion…

Upcoming Events in 2014

Fusion Antibodies will be attending the following events in 2014, we look forward to seeing you there! BioTrinity 2014European Biopartnering and Investment ConferenceLondon, May 12-14 2014 Biotech Outsourcing StrategiesCopenhagen, June…